The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.
about
Hepatitis C virus and neurological damageRedefining the viral reservoirs that prevent HIV-1 eradicationRole of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disordersMultiple Drug Transport Pathways through Human P-Glycoprotein.Targeting the Brain Reservoirs: Toward an HIV CureRaltegravir cerebrospinal fluid concentrations in HIV-1 infectionNanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.The Role of Caveolin 1 in HIV Infection and Pathogenesis.Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavirMeasuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?HIV-1 neuroimmunity in the era of antiretroviral therapy.Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapyPeptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitorsZidovudine and Lamivudine for HIV Infection.Drug transporter expression and localization in rat nasal respiratory and olfactory mucosa and olfactory bulb.Towards nanomedicines for neuroAIDS.Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Antiretroviral therapy CNS penetration and HIV-1-associated CNS diseaseHIV-associated neurocognitive disorders: perspective on management strategiesImpact of antiretroviral therapy on HIV-related brain injury.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.Sustained-release nanoART formulation for the treatment of neuroAIDSThe effect of HIV protease inhibitors on amyloid-β peptide degradation and synthesis in human cells and Alzheimer's disease animal modelComparative manufacture and cell-based delivery of antiretroviral nanoformulations.Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimersImperfect drug penetration leads to spatial monotherapy and rapid evolution of multidrug resistance.Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.Therapeutic amprenavir concentrations in cerebrospinal fluidClinically relevant drug-drug interactions between antiretrovirals and antifungalsDJ1 expression downregulates in neuroblastoma cells (SK-N-MC) chronically exposed to HIV-1 and cocaine.Metabolism of deoxypyrimidines and deoxypyrimidine antiviral analogs in isolated brain mitochondriaPreparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissue.Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.Altered Oligodendrocyte Maturation and Myelin Maintenance: The Role of Antiretrovirals in HIV-Associated Neurocognitive Disorders.Expression Profiling of Solute Carrier Gene Families at the Blood-CSF Barrier.Chronic lithium feeding reduces upregulated brain arachidonic acid metabolism in HIV-1 transgenic rat.A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier
P2860
Q26748575-C762D462-4143-4C07-BEB2-F1725316004FQ26827255-AE7DFD8F-D9EF-4B1A-B07B-203EE26DCA9DQ27025573-82E6824F-5493-4F54-BE31-B4AE65A6E6BEQ27301793-26543B04-EC25-429B-A432-9BBBF4307A47Q28075694-958F2A0A-524F-41A6-94F5-347AE0A948FEQ28476050-1D1385DB-5E45-48EE-915A-468A56B0AFB6Q30493643-556A42C1-5FDE-4E5C-B71F-ED3B251FFF13Q32183747-7F9E3222-E42B-41F8-9520-BD4E10C45E90Q33611816-EBF805D4-3CC1-420C-842D-AAD8358F5422Q33720712-4DC47E07-7E69-4A3C-933A-57AC345FF56DQ33733529-C685E266-EEAD-4F79-A47C-7CCDC1CA3929Q33962223-2D0DB533-CA11-4927-884A-C06514919AC4Q34194374-67BE3DEA-2F1F-4053-A6F4-FC9B7CC9F19CQ34194561-BE3F7E87-0481-4E20-B47B-DE0708F644B5Q34211080-1A91FDB9-3A69-427C-8F18-CEC5149613C8Q34495140-1F11378D-CB3C-4D5C-844F-01BDEFE2F1C3Q34497788-D8C4B1A6-5C9B-4E6C-8E7D-265B1C39B1DBQ34571360-E2FF52FC-6671-494F-9DF6-4489D60CF6D4Q34647014-3110EF7F-6C01-4CE2-993F-856D382843FCQ34652590-77607435-F2D6-49FF-A84A-986D9EA8488DQ34699119-09D0BEFE-1E0C-4B87-8E1D-261461C1406BQ34728884-E0EF87BF-5F07-48D3-88EF-0B4F0C81880DQ35071617-49F616E8-98B7-43E9-88E6-91857DC1B046Q35082009-22B6C669-3E72-40FC-A7A1-79F16611899DQ35570991-D36D0D07-725A-44F4-B2EB-245665AC789CQ35677168-16CCBCA3-773E-4E29-A6DE-656C52AC2034Q35683264-8B86CCCB-EE3D-4ECC-A67E-9F0CD08CB9C9Q35699612-52C4A992-9C6B-405F-8C4B-2E56DF7EA993Q35823231-F969D163-3F6F-4C7E-A732-34AD15FE9575Q35867483-74B44F4E-9C64-42B3-96AC-6E49959F4963Q35892563-BA4AFFB5-11DF-4C23-BDFA-344401377095Q35895155-CD33762A-2957-482A-99E5-608204434AA3Q36060187-79DF8066-40F2-496E-BAAE-1080E0DF5A5CQ36093283-CE3B3B95-E743-4701-AAF4-6EE7570EE29DQ36104280-BF2DA39B-E236-4027-8602-8F1B2C4872FBQ36107193-D7468D53-142E-4358-85C1-8C05C6CC22B2Q36169735-A8174A59-C608-46BC-86BA-CCC73C371713Q36186589-C65640B5-4CBE-402B-AF16-AA98E84C4242Q36338186-BA4F9A1E-C3DC-44BB-9862-20A570766ED5Q36522639-64D62715-52C3-41F3-90FF-9A230AB5967A
P2860
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The transport of anti-HIV drug ...... ndations for further research.
@en
The transport of anti-HIV drug ...... ndations for further research.
@nl
type
label
The transport of anti-HIV drug ...... ndations for further research.
@en
The transport of anti-HIV drug ...... ndations for further research.
@nl
prefLabel
The transport of anti-HIV drug ...... ndations for further research.
@en
The transport of anti-HIV drug ...... ndations for further research.
@nl
P2860
P921
P1433
P1476
The transport of anti-HIV drug ...... endations for further research
@en
P2093
Lavanya Varatharajan
P2860
P304
P356
10.1016/J.ANTIVIRAL.2008.12.013
P5008
P577
2009-01-25T00:00:00Z
2009-05-01T00:00:00Z